Long-term Pulmonary Safety of Inhaled Levodopa in Parkinson's Disease Subjects with Motor Fluctuations: A Phase 3 Open-label Randomized Study

被引：0
|
作者：
Grosset, Donald
Dhall, Rohit
Gurevich, Tanya
Kassubek, Jan
Poewe, Werner
Rascol, Olivier
Rudzinska, Monika
Cormier, Jennifer
Sedkov, Alexander
Oh, Charles
机构：
来源：
MOVEMENT DISORDERS | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
190
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [31] Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson's Disease
    Fung, V.
    Aldred, J.
    Bergquist, F.
    Danielsen, E.
    Jeong, A.
    Jia, J.
    Spiegel, A.
    Talapala, S.
    Carroll, C.
    MOVEMENT DISORDERS, 2023, 38 : S23 - S24
  • [32] A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease
    LeWitt, Peter A.
    Hauser, Robert A.
    Grosset, Donald G.
    Stocchi, Fabrizio
    Saint-Hilaire, Marie-Helene
    Ellenbogen, Aaron
    Leinonen, Mika
    Hampson, Neil B.
    DeFeo-Fraulini, Tia
    Freed, Martin I.
    Kieburtz, Karl D.
    MOVEMENT DISORDERS, 2016, 31 (09) : 1356 - 1365
  • [33] Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations: An Open-Label Observational Study
    Zangaglia, Roberta
    Stocchi, Fabrizio
    Sciarretta, Massimo
    Antonini, Angelo
    Mancini, Francesca
    Guidi, Marco
    Martignoni, Emilia
    Pacchetti, Claudio
    CLINICAL NEUROPHARMACOLOGY, 2010, 33 (02) : 61 - 66
  • [34] Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study
    Kassubek, Jan
    Factor, Stewart A.
    Balaguer, Ernest
    Schwarz, Johannes
    Chaudhuri, K. Ray
    Isaacson, Stuart H.
    Wu, Stacy
    Muhr, Carmen Denecke
    Kulisevsky, Jaime
    JOURNAL OF NEUROLOGY, 2024, 271 (06) : 3554 - 3570
  • [35] Levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations: Interim safety and motor-symptom endpoints in an ongoing, open-label study
    Espay, A. J.
    Vanagunas, A. D.
    Hauser, R. A.
    Fernandez, H. H.
    Standaert, D. G.
    Odin, P.
    Pritchett, Y.
    Widnell, K. L.
    Chatamra, K.
    Benesh, J.
    Lenz, R. A.
    MOVEMENT DISORDERS, 2012, 27 : S117 - S117
  • [36] Pharmacokinetics of etilevodopa compared to levodopa in patient's with Parkinson's disease: An open-label, randomized, crossover study
    Djaldetti, R
    Giladi, N
    Hassin-Baer, S
    Shabtai, H
    Melamed, E
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (06) : 322 - 326
  • [37] Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson<acute accent>s Disease
    Peball, Marina
    Heim, Beatrice
    Carbone, Federico
    Schorr, Oliver
    Werkmann, Mario
    Ellmerer, Philipp
    Marini, Kathrin
    Krismer, Florian
    Knaus, Hans-Guenther
    Poewe, Werner
    Djamshidian, Atbin
    Seppi, Klaus
    NPJ PARKINSONS DISEASE, 2024, 10 (01)
  • [38] Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An open-label extension study
    Poewe, W
    NEUROLOGY, 2005, 64 (06) : A105 - A105
  • [39] Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An open-label extension study
    Poewe, W
    MOVEMENT DISORDERS, 2005, 20 : S72 - S72
  • [40] Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study
    Waxman, Aaron
    Restrepo-Jaramillo, Ricardo
    Thenappan, Thenappan
    Engel, Peter
    Bajwa, Abubakr
    Ravichandran, Ashwin
    Feldman, Jeremy
    Case, Amy Hajari
    Argula, Rahul G.
    Tapson, Victor
    Smith, Peter
    Deng, Chunqin
    Shen, Eric
    Nathan, Steven D.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (06)
12345